688131 皓元医药
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,646,27828.52%2,876,8962,270,1781,880,0471,358,054
减:营业总成本2,175,28828.53%2,442,4691,900,8821,672,7071,144,721
    其中:营业成本1,301,63225.79%1,521,7761,181,2791,030,874659,411
               财务费用96,640150.37%63,03434,51631,850(578)
               资产减值损失(132,749)48.21%(134,088)(131,360)(83,999)(43,376)
公允价值变动收益434267.41%74150----
投资收益(679)-225.57%(15,967)(13,758)(4,772)16,053
    其中:对联营企业和合营企业的投资收益(4,894)-29.54%(8,514)(13,771)(6,113)(2,746)
营业利润347,45220.07%296,753236,817128,329196,567
利润总额346,04920.40%275,776238,355128,193198,543
减:所得税费用53,082-4.78%44,13040,4251,8856,986
净利润292,96726.45%231,645197,930126,308191,558
减:非控股权益(15,853)218.33%(8,161)(3,660)(1,142)(2,086)
股东净利润308,82030.49%239,807201,590127,449193,643

市场价值指针
每股收益 (元) *1.45029.46%1.1300.9600.6101.330
每股派息 (元) *0.09012.50%0.2300.1900.1500.380
每股净资产 (元) *15.67510.15%14.34313.10916.68421.690
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容